Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual treatments with the substances.
This time, Incannex Healthcare IXHL has placed a purchase order for the Toronto-based company’s proprietary MDMA “LaNeo” as well as psilocybin to be used in several planned clinical studies.
The agreement follows Melbourne, Australia-based Incannex’s announced plans to create a subsidiary to work with the country on legalizing MDMA for PTSD treatment and psilocybin for that of Treatment-Resistant Depression.
See Also: Using LSD To Treat Anxiety Is Showing Some Encouraging Findings In A Clinical Trial
The new company would open a first “model” clinic providing the mentioned psychedelic-assisted therapies sometime this year.
Meanwhile, Incannex holds an ongoing Phase 2a clinical trial on psilocybin-assisted therapy for Generalized Anxiety Disorder.
On behalf of PharmAla, the company recently partnered with also psychedelics business Mindset Pharma MSSTF to supply clinical-grade psilocybin to Little Green Pharma’s subsidiary Reset Mind Sciences Ltd. for a clinical trial on patients with treatment-resistant, Major Depressive Disorder.
Additionally, PharmAla provided its MDMA to Australian company Emyria Ltd. for research purposes, and further submitted a national trademark application for LaNeo as well as the company’s brand name including both EU-GMP MDMA and EU-GMP psilocybin products.
ICYMI: Exclusive Coverage From the Benzinga Psychedelics Capital Conference 2023:
-
MDMA Therapy Experts Debate Upcoming Approval, Psychedelic Market Opps
-
Ketamine Therapy Leaders Share Bold Vision For Future Of Psychedelics
-
In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
-
Fireside With Enveric Biosciences's Dr. Tucker, Unlocking Psychedelic Healing Benefits
-
Making The World A Better Place, How Psychedelics Are Helping
Photo: Benzinga edit with photo by PublicDomainPictures and sergeitokmakov on Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!